Export 8 results:
Author Title [ Type(Desc)] Year
Filters: Author is Giralt, Sergio  [Clear All Filters]
Journal Article
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.”, J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
V. T. Ho, Cutler, C., Carter, S., Martin, P., Adams, R., Horowitz, M., Ferrara, J., Soiffer, R., and Giralt, S., “Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.”, Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
Q. Bashir, Nishihori, T., Pasquini, M. C., Martens, M. J., Wu, J., Alsina, M., Anasetti, C., Brunstein, C., Dawson, P., Efebera, Y., Gasparetto, C., Geller, N., Giralt, S., Hall, A. C., Koreth, J., McCarthy, P., Scott, E., Stadtmauer, E. A., Vesole, D. H., and Hari, P., “A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial”, Transplant Cell Ther, vol. S2666-6367, no. 22, pp. 01467-1, 2022.
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., Wingard, J. R., Difronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.